<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276952</url>
  </required_header>
  <id_info>
    <org_study_id>HCUCH-NL-GTX-002</org_study_id>
    <nct_id>NCT00276952</nct_id>
  </id_info>
  <brief_title>Gonyautoxin in the Treatment of Chronic Tension-Type Headache</brief_title>
  <official_title>Phase 2 Study of Treatment of Chronic Tension-Type Headache Using Gonyautoxins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of Gonyautoxin 2/3 epimers in&#xD;
      the treatment of patients diagnosed with chronic tensional-type headache in accordance with&#xD;
      International Headache Society guidelines&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gonyautoxin are phycotoxins, whose molecular mechanism of action is a reversible block of the&#xD;
      voltage-gated sodium channels at neuronal level. They are axonal conduction blockers impeding&#xD;
      nerve impulse propagation. In order to evaluate the clinical efficacy of Gonyautoxin 2/3&#xD;
      epimers in the treatment of patients diagnosed with chronic tensional-type headache, the&#xD;
      patients were locally injected with placebo versus Gonyautoxin following a painful spots&#xD;
      injection standarized protocol&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2004</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a) Drop off in the patient acute headache pain (2 minutes, weekly for 20 weeks)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>b) Number of days without headache pain following infiltration</measure>
  </primary_outcome>
  <enrollment>27</enrollment>
  <condition>Tension-Type Headache</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonyautoxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic tensional-type headache patients according to the International Headache&#xD;
             Society criteria: patients with headache of a pressing or tightening quality with&#xD;
             episodic frequency above 15 days a month&#xD;
&#xD;
          -  Refractory to conventional treatments such as, orally administered analgesics,&#xD;
             systemic muscular relaxant, corticoids and antidepressant like Amytriptiline&#xD;
&#xD;
          -  Treated and controlled in the University Hospital Neurology Clinic over 2 years with&#xD;
             duration of symptoms over 3 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of headache prophylactic treatment a month prior to infiltration&#xD;
&#xD;
          -  Myasthenic syndromes&#xD;
&#xD;
          -  Muscular dystrophies&#xD;
&#xD;
          -  Inflammatory myopathies&#xD;
&#xD;
          -  Acute and chronic polineuropathies&#xD;
&#xD;
          -  Use of psychotropic substances 24-hour before infiltration&#xD;
&#xD;
          -  Anticoagulant treatment&#xD;
&#xD;
          -  terminal illnesses (AIDS, cancer)&#xD;
&#xD;
          -  drugs or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nestor Lagos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine University of Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departament of Neurology and Neurosurgery, Hospital Cl√≠nico Universidad de Chile.</name>
      <address>
        <city>Santiago</city>
        <zip>0</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>January 12, 2006</last_update_submitted>
  <last_update_submitted_qc>January 12, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2006</last_update_posted>
  <keyword>Gonyautoxins</keyword>
  <keyword>Tension-type Headache</keyword>
  <keyword>Human Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tension-Type Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

